NSE · SUNPHARMA.NS
Sun Pharmaceutical Industries Limited
₹1,812.10+₹51.10 (+2.9%)
Sun Pharmaceutical Industries Limited’s quoted price sits in the lower half of its reported 52-week range, 11.48% below the high.
Loading market information…
NSE · MEDICAMEQ.NS · INR
Stock price, dividends, earnings
Quote as of Oct 30, 2026, 07:20 AM UTC. Cached market data; not a live quote.
One-year closing-price history · INR. Historical prices are not a forecast.
Medicamen Biotech Limited’s quoted price sits in the lower half of its reported 52-week range, 39.91% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
THE INCOME SIDE
Medicamen Biotech Limited’s forward annual dividend is ₹1.00 per share, paid annual. The forward yield is 0.37% at the quoted price. Future payments can change.
Historical amounts are adjusted for stock splits. Understand ex-dividend and payment dates →
BEHIND THE RESULTS
Upcoming dates and analyst estimates may change. Fiscal quarters follow Medicamen Biotech Limited’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Medicamen Biotech Limited, established in 1993 and headquartered in New Delhi, India, is an Indian pharmaceutical firm primarily engaged in the manufacturing and distribution of a diverse range of medicinal formulations. Its product line encompasses various dosage formats, including tablets, capsules, liquid and dry syrups, and topical ointments. The company further extends its portfolio to specialized items such as oral rehydration solutions, mouthwashes, and dental care products.
Latest available per-share figures in INR. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 07:21 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
Completed calendar years and any current-year payments shown separately. Current-year totals are incomplete until all payments are made.
See annual income at the current dividend rate.
Assumes the annual dividend stays unchanged. Payments follow the company’s schedule. Excludes taxes, fees and currency changes.
| Q2 2025 |
|---|
| Nov 14, 2024 |
| ₹1.15-67.14% vs estimate |
| ₹447.43M+7.31% vs estimate |
| Q1 2025 | Aug 13, 2024 | ₹1.06 | ₹430.49M |
|---|
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
₹1,812.10+₹51.10 (+2.9%)
Sun Pharmaceutical Industries Limited’s quoted price sits in the lower half of its reported 52-week range, 11.48% below the high.
₹9,811.00+₹147.00 (+1.52%)
Divi's Laboratories Limited’s quoted price sits in the upper half of its reported 52-week range, 0.35% below the high.
₹1,267.10-₹22.20 (-1.72%)
Venus Remedies Limited’s quoted price sits in the upper half of its reported 52-week range, 37.73% below the high.
₹448.50-₹8.50 (-1.86%)
Bafna Pharmaceuticals Limited’s quoted price sits in the upper half of its reported 52-week range, 6.55% below the high.
₹136.08-₹0.46 (-0.34%)
ZIM Laboratories Limited’s quoted price sits in the upper half of its reported 52-week range, 14.85% below the high.
₹205.52-₹3.62 (-1.73%)
Kilitch Drugs (India) Limited’s quoted price sits in the upper half of its reported 52-week range, 23.11% below the high.
₹767.40-₹0.55 (-0.07%)
Albert David Limited’s quoted price sits in the upper half of its reported 52-week range, 17.65% below the high.
₹18.67-₹0.31 (-1.63%)
Medico Remedies Limited’s quoted price sits in the lower half of its reported 52-week range, 67.18% below the high.
